BCAX
Bicara Therapeutics Inc.
$21.69
+1.93%
$1.4B
No data for this timeframe.
Vol
Market Cap$1.4B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (81%)
Inst. Holders50 funds
Inst. Value$542.1M
Inst. Activity8 buys / 5 sells
Insider Activity2B / 15S
Insider Net $$37.1M
SEC Reports10
Press Releases3
Recent Activity
Jun 11, 2026
SEC
An institutional cluster for Bicara Therapeutics (BCAX) shows net bearish conviction in Q3 2025: 3 sellers (including a
INST-CLUSTER — Impact 5/10
Jun 9, 2026
Insider
POWELL MICHAEL was granted 19,475 shares
Director
Jun 9, 2026
Insider
Simson Jake was granted 19,475 shares
Director
Jun 9, 2026
Insider
Haviland Kate was granted 19,475 shares
Director
May 26, 2026
SEC
Three top BCAX insiders (CEO, CFO, COO) sold a combined $590K in open-market shares over a 7-day window. The CFO's sale
CLUSTER — Impact 2/10
May 21, 2026
fda
Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC
<p align="center"> <em>At a median follow-up of three years, 1500mg of ficerafusp alfa weekly in c
May 11, 2026
SEC
Bicara Therapeutics reported Q1 2026 net loss of $56.2M ($-0.93/share), wider than the $-0.68 loss in Q1 2025, driven by
8-K — Impact 4/10
Inst.
JANUS HENDERSON GROUP PLC — ADD
3,326,918 shares ($66.1M)
Price Targets
$31.46
+45.1% upside
Strong Buy
Current $21.69
Low $16.00
Median $31.00
High $46.00
13 analysts
$16.00
$46.00
Analyst Ratings
7Strong Buy
10Buy
4Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 12, 2026 | Goldman Sachs | MAINTAIN | Neutral → Neutral |
| May 12, 2026 | Morgan Stanley | MAINTAIN | Overweight → Overweight |
| May 11, 2026 | Guggenheim | INITIATE | Buy |
| Mar 31, 2026 | Goldman Sachs | MAINTAIN | Neutral → Neutral |
| Mar 31, 2026 | Wedbush | REITERATE | Outperform → Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.83 | $-1.04 — $-0.51 | -65% YoY | 13 |
| Next Q | $-0.85 | $-1.02 — $-0.51 | -27% YoY | 13 |
| Current FY | $-3.48 | $-4.08 — $-2.52 | -38% YoY | 13 |
| Next FY | $-3.63 | $-5.05 — $-2.68 | -4% YoY | 12 |
Latest Reports
BEARISH
INST-CLUSTER
5/10
An institutional cluster for Bicara Therapeutics (BCAX) shows net bearish conviction in Q3 2025: 3 sellers (including a
Jun 11, 2026
NEUTRAL
CLUSTER
2/10
Three top BCAX insiders (CEO, CFO, COO) sold a combined $590K in open-market shares over a 7-day window. The CFO's sale
May 26, 2026
NEUTRAL
Press
2/10
Bicara Therapeutics granted a stock option to purchase 44,175 shares to a new employee as an inducement to join the comp
Apr 3, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | $144.3M | — |
| JANUS HENDERSON GROUP PLC | $66.1M | ADD |
| BlackRock, Inc. | $56.6M | — |
| FMR LLC | $41.8M | TRIM |
| VANGUARD CAPITAL MANAGEMENT LLC | $35.3M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 9, 2026 | POWELL MICHAEL | A | $0.00 |
| Jun 9, 2026 | Simson Jake | A | $0.00 |
| Jun 9, 2026 | Haviland Kate | A | $0.00 |
| Jun 9, 2026 | Mazumdar-Shaw Kiran | A | $0.00 |
| Jun 9, 2026 | Robertson Scott | A | $0.00 |
50 institutional holders with $542.1M total value (27,223,825 shares) as of 2026-Q1. Top holders: RA, JANUS, BlackRock,. Net buying activity: 8 institutions added/increased vs 5 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | 7,255,993 | $144.3M | 26.6% | — |
| 2 | JANUS HENDERSON GROUP PLC | 3,326,918 | $66.1M | 12.2% | ADD +25.7% |
| 3 | BlackRock, Inc. | 2,843,707 | $56.6M | 10.4% | — |
| 4 | FMR LLC | 2,100,929 | $41.8M | 7.7% | TRIM -37.2% |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 1,774,220 | $35.3M | 6.5% | — |
| 6 | CITADEL ADVISORS LLC | 1,659,342 | $33.0M | 6.1% | — |
| 7 | FRANKLIN RESOURCES INC | 1,621,643 | $32.3M | 5.9% | NEW |
| 8 | STATE STREET CORP | 1,419,388 | $28.2M | 5.2% | DOUBLED +179.5% |
| 9 | FIL Ltd | 679,904 | $13.5M | 2.5% | — |
| 10 | GOLDMAN SACHS GROUP INC | 558,964 | $11.1M | 2.1% | — |
| 11 | MORGAN STANLEY | 421,219 | $8.4M | 1.5% | DOUBLED +284.8% |
| 12 | BANK OF AMERICA CORP /DE/ | 327,989 | $6.5M | 1.2% | TRIM -26.5% |
| 13 | VANGUARD PORTFOLIO MANAGEMENT LLC | 290,939 | $5.8M | 1.1% | — |
| 14 | Clearbridge Investments, LLC | 289,221 | $5.8M | 1.1% | — |
| 15 | D. E. Shaw & Co., Inc. | 276,943 | $5.5M | 1.0% | — |
| 16 | TD ASSET MANAGEMENT INC | 269,718 | $5.4M | 1.0% | ADD +32.2% |
| 17 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 263,985 | $5.3M | 1.0% | ADD +45.5% |
| 18 | Hudson Bay Capital Management LP | 233,703 | $4.6M | 0.9% | ADD +55.8% |
| 19 | Woodline Partners LP | 232,690 | $4.6M | 0.9% | TRIM -33.3% |
| 20 | VANGUARD FIDUCIARY TRUST CO | 216,753 | $4.3M | 0.8% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | ADD | 2,646,285 | 3,326,918 | +25.7% | $66.1M | 2026-Q1 |
| FMR LLC | TRIM | 3,347,223 | 2,100,929 | -37.2% | $41.8M | 2026-Q1 |
| MORGAN STANLEY | DOUBLED | 109,456 | 421,219 | +284.8% | $8.4M | 2026-Q1 |
| Hudson Bay Capital Management LP | ADD | 150,000 | 233,703 | +55.8% | $4.6M | 2026-Q1 |
| DIMENSIONAL FUND ADVISORS LP | DOUBLED | 40,934 | 109,261 | +166.9% | $2.2M | 2026-Q1 |
| Rafferty Asset Management, LLC | TRIM | 59,819 | 38,003 | -36.5% | $755.9K | 2026-Q1 |
| Invesco Ltd. | ADD | 21,006 | 31,650 | +50.7% | $629.5K | 2026-Q1 |
| Legal & General Group Plc | ADD | 15,958 | 22,227 | +39.3% | $442.1K | 2026-Q1 |
| Russell Investments Group, Ltd. | TRIM | 56,598 | 19,893 | -64.9% | $395.7K | 2026-Q1 |
| GROUP ONE TRADING LLC | NEAR_EXIT | 16,914 | 1,306 | -92.3% | $26.0K | 2026-Q1 |
| Rockefeller Capital Management L.P. | DOUBLED | 121 | 601 | +396.7% | $12.0K | 2026-Q1 |
| NISA INVESTMENT ADVISORS, LLC | TRIM | 570 | 161 | -71.8% | $3.2K | 2026-Q1 |
| Allworth Financial LP | ADD | 53 | 74 | +39.6% | $1.5K | 2026-Q1 |
| JANUS HENDERSON GROUP PLC | NEW | — | 2,646,285 | — | $44.5M | 2025-Q4 |
| STATE STREET CORP | DOUBLED | 590,277 | 1,649,537 | +179.5% | $27.8M | 2025-Q4 |
| FRANKLIN RESOURCES INC | NEW | — | 1,620,025 | — | $27.3M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 456,621 | 335,682 | -26.5% | $5.6M | 2025-Q4 |
| TD ASSET MANAGEMENT INC | ADD | 184,982 | 244,626 | +32.2% | $4.1M | 2025-Q4 |
| Woodline Partners LP | TRIM | 348,690 | 232,690 | -33.3% | $3.9M | 2025-Q4 |
| Russell Investments Group, Ltd. | ADD | 39,126 | 56,598 | +44.7% | $952.6K | 2025-Q4 |
| ALPS ADVISORS INC | ADD | 26,378 | 44,978 | +70.5% | $757.0K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 25,924 | 35,243 | +35.9% | $593.1K | 2025-Q4 |
| ALLIANCEBERNSTEIN L.P. | TRIM | 40,770 | 29,110 | -28.6% | $489.9K | 2025-Q4 |
| TUDOR INVESTMENT CORP ET AL | ADD | 18,730 | 27,391 | +46.2% | $461.0K | 2025-Q4 |
| Legal & General Group Plc | DOUBLED | 3,156 | 15,958 | +405.6% | $268.6K | 2025-Q4 |
13 unique insiders with 50 transactions. Net insider value: $37.1M ($40.0M bought, $2.9M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 9, 2026 | POWELL MICHAEL | Director | AWARD | 19,475 | — | — |
| Jun 9, 2026 | Simson Jake | Director | AWARD | 19,475 | — | — |
| Jun 9, 2026 | Haviland Kate | Director | AWARD | 19,475 | — | — |
| Jun 9, 2026 | Mazumdar-Shaw Kiran | Director | AWARD | 19,475 | — | — |
| Jun 9, 2026 | Robertson Scott M. | Director | AWARD | 19,475 | — | — |
| Jun 9, 2026 | Bowden Christopher | Director | AWARD | 19,475 | — | — |
| Jun 9, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director | AWARD | 19,475 | — | — |
| May 21, 2026 | Hyep Ivan | Chief Financial Officer | EXERCISE | 9,200 | $3.79 | $34.9K |
| May 21, 2026 | Hyep Ivan | Chief Financial Officer | SELL | 9,200 | $20.42 | $187.9K |
| May 18, 2026 | Mazumdar Claire | Chief Executive Officer | EXERCISE | 15,000 | $3.79 | $56.8K |
| May 18, 2026 | Mazumdar Claire | Chief Executive Officer | SELL | 12,022 | $19.96 | $240.0K |
| May 15, 2026 | Cohlhepp Ryan | President and COO | EXERCISE | 8,000 | $3.79 | $30.3K |
| May 15, 2026 | Cohlhepp Ryan | President and COO | SELL | 8,000 | $20.29 | $162.3K |
| May 8, 2026 | Schelman William | Chief Medical Officer | AWARD | 85,000 | — | — |
| Apr 27, 2026 | Raben David | Chief Medical Officer | EXERCISE | 5,500 | $3.79 | $20.8K |
| Apr 27, 2026 | Raben David | Chief Medical Officer | SELL | 5,500 | $22.88 | $125.8K |
| Apr 21, 2026 | Hyep Ivan | Chief Financial Officer | EXERCISE | 9,200 | $3.79 | $34.9K |
| Apr 21, 2026 | Hyep Ivan | Chief Financial Officer | SELL | 9,200 | $23.00 | $211.6K |
| Apr 20, 2026 | Mazumdar Claire | Chief Executive Officer | EXERCISE | 15,000 | $3.79 | $56.8K |
| Apr 20, 2026 | Mazumdar Claire | Chief Executive Officer | SELL | 15,000 | $23.61 | $354.1K |
| Apr 16, 2026 | Mazumdar Claire | Chief Executive Officer | EXERCISE | 8,226 | $4.44 | $36.5K |
| Apr 15, 2026 | Cohlhepp Ryan | President and COO | EXERCISE | 8,000 | $3.79 | $30.3K |
| Apr 15, 2026 | Cohlhepp Ryan | President and COO | SELL | 8,000 | $23.01 | $184.1K |
| Mar 25, 2026 | Raben David | Chief Medical Officer | EXERCISE | 5,500 | $3.79 | $20.8K |
| Mar 25, 2026 | Raben David | Chief Medical Officer | SELL | 5,500 | $18.95 | $104.2K |
| Mar 23, 2026 | Hyep Ivan | Chief Financial Officer | SELL | 9,200 | $18.52 | $170.3K |
| Mar 23, 2026 | Hyep Ivan | Chief Financial Officer | EXERCISE | 9,200 | $3.79 | $34.9K |
| Mar 20, 2026 | Mazumdar Claire | Chief Executive Officer | EXERCISE | 1,596 | $3.79 | $6.0K |
| Mar 20, 2026 | Mazumdar Claire | Chief Executive Officer | SELL | 1,596 | $18.95 | $30.2K |
| Mar 19, 2026 | Mazumdar Claire | Chief Executive Officer | EXERCISE | 6,905 | $3.79 | $26.2K |
| Mar 19, 2026 | Mazumdar Claire | Chief Executive Officer | SELL | 6,905 | $18.78 | $129.7K |
| Mar 18, 2026 | Mazumdar Claire | Chief Executive Officer | EXERCISE | 6,499 | $3.79 | $24.6K |
| Mar 18, 2026 | Mazumdar Claire | Chief Executive Officer | SELL | 6,499 | $18.84 | $122.4K |
| Mar 16, 2026 | Cohlhepp Ryan | President and COO | SELL | 8,000 | $19.66 | $157.3K |
| Mar 16, 2026 | Cohlhepp Ryan | President and COO | EXERCISE | 8,000 | $3.79 | $30.3K |
| Mar 9, 2026 | Mazumdar Claire | Chief Executive Officer | SELL | 36,766 | $19.17 | $704.7K |
| Mar 9, 2026 | Mazumdar Claire | Chief Executive Officer | EXERCISE | 36,766 | $3.79 | $139.3K |
| Mar 6, 2026 | Mazumdar Claire | Chief Executive Officer | EXERCISE | 3,817 | $3.79 | $14.5K |
| Mar 5, 2026 | Mazumdar Claire | Chief Executive Officer | EXERCISE | 1,786 | $3.79 | $6.8K |
| Mar 4, 2026 | Mazumdar Claire | Chief Executive Officer | EXERCISE | 2,631 | $3.79 | $10.0K |
| Mar 4, 2026 | Hyep Ivan | Chief Financial Officer | EXERCISE | 2,963 | $3.79 | $11.2K |
| Mar 4, 2026 | Raben David | Chief Medical Officer | EXERCISE | 16,300 | $3.79 | $61.8K |
| Mar 3, 2026 | Raben David | Chief Medical Officer | EXERCISE | 200 | $3.79 | $757.96 |
| Mar 3, 2026 | Cohlhepp Ryan | President and COO | EXERCISE | 12,892 | $3.79 | $48.9K |
| Mar 3, 2026 | Hyep Ivan | Chief Financial Officer | EXERCISE | 7,318 | $3.79 | $27.7K |
| Feb 26, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director | BUY | 300,000 | $16.00 | $4.8M |
| Feb 26, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director | BUY | 2,200,000 | $16.00 | $35.2M |
| Feb 25, 2026 | Cohlhepp Ryan | President and COO | EXERCISE | 3,108 | $3.79 | $11.8K |
| Feb 25, 2026 | Cohlhepp Ryan | President and COO | SELL | 3,108 | $18.04 | $56.1K |
| Feb 2, 2026 | Meisner Lara | Chief Legal Officer | AWARD | 90,000 | — | — |
10 SEC filing reports analyzed. Sentiment: 0 bullish, 2 bearish, 0 mixed, 8 neutral. Avg impact: 3.6/10.
BEARISH
INST-CLUSTER
5/10
An institutional cluster for Bicara Therapeutics (BCAX) shows net bearish conviction in Q3 2025: 3 s
Jun 11, 2026
NEUTRAL
CLUSTER
2/10
Three top BCAX insiders (CEO, CFO, COO) sold a combined $590K in open-market shares over a 7-day win
May 26, 2026
NEUTRAL
8-K
4/10
Bicara Therapeutics reported Q1 2026 net loss of $56.2M ($-0.93/share), wider than the $-0.68 loss i
May 11, 2026
NEUTRAL
PRESS-RELEASE
2/10
Bicara Therapeutics announced it will report Q1 2026 financial results on May 11, 2026, with a confe
May 4, 2026
NEUTRAL
CLUSTER
2/10
Three top executives (CEO, CFO, CMO) sold a combined $692K in BCAX stock over the past week, but thi
Apr 28, 2026
NEUTRAL
DEFA14A
2/10
Bicara Therapeutics Inc. filed a definitive proxy statement for a shareholder vote on director elect
Apr 27, 2026
NEUTRAL
CLUSTER
5/10
Three top executives at Bicara Therapeutics — including the CEO, CFO, and President/COO — collective
Apr 22, 2026
BEARISH
CLUSTER
7/10
Bicara Therapeutics executives Claire Mazumdar (CEO) and Ryan Cohlhepp (President/COO) sold a combin
Apr 20, 2026
NEUTRAL
CLUSTER
4/10
Multiple C-suite executives at Bicara Therapeutics (BCAX) exercised stock options and sold shares in
Mar 24, 2026
NEUTRAL
CLUSTER
3/10
CEO Claire Mazumdar and President Ryan Cohlhepp of Bicara Therapeutics (BCAX) exercised stock option
Mar 20, 2026
NEUTRAL
2/10
Bicara Therapeutics granted a stock option to purchase 44,175 shares to a new employee as an inducem
Apr 3, 2026
NEUTRAL
3/10
Bicara Therapeutics announced it will report its Q4 and full-year 2025 financial results on March 30
Mar 23, 2026
NEUTRAL
3/10
Bicara Therapeutics granted a stock option to purchase 115,000 shares to a new employee as an induce
Mar 4, 2026
Current analyst consensus: Strong Buy (81% buy). Based on 21 analysts: 7 strong buy, 10 buy, 4 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$31.46 mean target
+45.1% upside
Strong Buy (1.60)
$16.00 Low
$46.00 High
| Metric | Value |
|---|---|
| Current Price | $21.69 |
| Target Low | $16.00 |
| Target Mean | $31.46 |
| Target Median | $31.00 |
| Target High | $46.00 |
| # Analysts | 13 |
| Recommendation | Strong Buy (1.60) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.83 | $-1.04 | $-0.51 | -65.1% | — | 1↑ 7↓ | $0.0B | 0.0% | 13 |
| Next Q 2026-09-30 |
$-0.85 | $-1.02 | $-0.51 | -26.6% | — | 1↑ 7↓ | $0.0B | 0.0% | 13 |
| Current FY 2026-12-31 |
$-3.48 | $-4.08 | $-2.52 | -38.0% | — | 0↑ 11↓ | $0.0B | 0.0% | 13 |
| Next FY 2027-12-31 |
$-3.63 | $-5.05 | $-2.68 | -4.4% | — | 0↑ 7↓ | $0.0B | 0.0% | 12 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.825 | |
| 7d ago | $-0.807 | -0.018 |
| 30d ago | $0.000 | -0.825 |
| 60d ago | $0.000 | -0.825 |
| 90d ago | $-0.725 | -0.100 |
10 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 5 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 12, 2026 | Goldman Sachs | MAINTAIN | Neutral | Neutral |
| May 12, 2026 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| May 11, 2026 | Guggenheim | INITIATE | — | Buy |
| Mar 31, 2026 | Goldman Sachs | MAINTAIN | Neutral | Neutral |
| Mar 31, 2026 | Wedbush | REITERATE | Outperform | Outperform |
| Mar 31, 2026 | Wells Fargo | MAINTAIN | Equal-Weight | Equal-Weight |
| Mar 31, 2026 | Citizens | REITERATE | Market Outperform | Market Outperform |
| Mar 31, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 25, 2026 | B of A Securities | INITIATE | — | Buy |
| Jan 29, 2026 | Citizens | INITIATE | — | Market Outperform |
| Jan 13, 2026 | Wedbush | REITERATE | Outperform | Outperform |
| Jan 8, 2026 | BTIG | INITIATE | — | Buy |
| Dec 18, 2025 | Mizuho | INITIATE | — | Neutral |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 7 | 10 | 4 | 0 | 0 | 81% | |
| May 1, 2026 | 6 | 10 | 4 | 0 | 0 | 80% | |
| Apr 1, 2026 | 6 | 10 | 4 | 0 | 0 | 80% | |
| Mar 1, 2026 | 5 | 10 | 4 | 0 | 0 | 79% | |
| Feb 1, 2026 | 5 | 10 | 3 | 0 | 0 | 83% | |
| Jan 1, 2026 | 4 | 9 | 3 | 0 | 0 | 81% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 21, 2026
fda
Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC
<p align="center"> <em>At a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembrolizumab demonstrated an esti
May 14, 2026
short_volume
Short Volume: BCAX — 84.7% short (0.5M / 0.5M)
Short: 463,204 | Exempt: 0 | TRF Vol: 546,715 | Short Ratio: 84.7% | Off-exchange volume (dark pool + OTC)
May 13, 2026
activist
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
<p align="justify">BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company comm
May 13, 2026
short_volume
Short Volume: BCAX — 90.6% short (0.5M / 0.5M)
Short: 470,682 | Exempt: 0 | TRF Vol: 519,255 | Short Ratio: 90.6% | Off-exchange volume (dark pool + OTC)
May 11, 2026
earnings
Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
<p align="center"><em>Study to evaluate ficerafusp alfa in combination with pembrolizumab as a loading and every-three-week maintenance regimen in 1L
May 11, 2026
earnings_calendar
BCAX Q1 2026 Earnings Scheduled — 2026-05-11
May 4, 2026
earnings
Bicara Therapeutics to Report First Quarter 2026 Financial Results and Business Updates on May 11, 2026, at 8:30 AM ET
<p>BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringin
Apr 3, 2026
contract
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
<p align="justify">BOSTON, April 03, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company co
Mar 30, 2026
earnings
Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
<p align="center"><em>Selected 1500mg weekly of ficerafusp alfa as the optimal dose and initiated Phase 3 of the FORTIFI-HN01 pivotal trial; interim a
Mar 30, 2026
earnings_calendar
BCAX Q4 2025 Earnings Scheduled — 2026-03-30
Mar 26, 2026
earnings_calendar
BCAX Q4 2025 Earnings Scheduled — 2026-03-26
Mar 23, 2026
earnings
Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET
<p align="justify">BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company co
Mar 17, 2026
short_interest
FTD: BCAX — 113,444 shares ($2.2M) failed to deliver
Settlement: 20260317, Price: $19.40, FTD Value: $2,200,813.6, BICARA THERAPEUTICS INC COM
Mar 11, 2026
short_interest
FTD: BCAX — 100,235 shares ($2.0M) failed to deliver
Settlement: 20260311, Price: $20.06, FTD Value: $2,010,714.1, BICARA THERAPEUTICS INC COM
Mar 10, 2026
short_interest
FTD: BCAX — 30,623 shares ($0.6M) failed to deliver
Settlement: 20260310, Price: $19.70, FTD Value: $603,273.1, BICARA THERAPEUTICS INC COM